NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS Stock Report

Market Cap: US$2.0b

NewAmsterdam Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:NAMS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Dec 24SellUS$427,437Forbion Capital Partners B.V.Company16,738US$25.54
27 Dec 24SellUS$1,091,257Forbion Capital Partners B.V.Company42,009US$26.01
24 Dec 24SellUS$1,306,397Forbion Capital Partners B.V.Company51,071US$26.13
19 Dec 24SellUS$2,280,643Forbion Capital Partners B.V.Company88,178US$26.55
16 Dec 24SellUS$27,400Forbion Capital Partners B.V.Company1,096US$25.00
13 Dec 24BuyUS$85,250,441Frazier Life Sciences Management, LPCompany3,689,475US$24.50
13 Dec 24SellUS$2,647,107Forbion Capital Partners B.V.Company104,409US$26.18
13 Dec 24SellUS$364,635Forbion Capital Partners B.V.Company14,441US$25.25
11 Dec 24SellUS$6,584,161Forbion Capital Partners B.V.Company259,252US$27.11
18 Nov 24SellUS$587,646Forbion Capital Partners B.V.Company23,443US$25.08
14 Nov 24SellUS$260,809Forbion Capital Partners B.V.Company10,430US$25.01
26 Sep 24BuyUS$17,333Juliette AudetIndividual1,104US$15.70
20 Aug 24BuyUS$81,350Michael DavidsonIndividual5,000US$16.27
20 Jun 24BuyUS$86,309Michael DavidsonIndividual5,000US$17.26
26 Mar 24BuyUS$181,224Frazier Life Sciences Management, LPCompany8,429US$21.50

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NAMS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders956,5450.894%
General Public1,815,2931.7%
Hedge Funds6,978,5346.52%
VC/PE Firms46,077,70943%
Institutions51,225,13847.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.3%.

Top Shareholders

Top 25 shareholders own 87.73% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.9%
Frazier Life Sciences Management, LP
15,916,418US$295.6m23.8%13.23%
10%
Bain Capital Life Sciences Investors, LLC
10,719,110US$199.1m2.34%29.22%
9.9%
Forbion Capital Partners B.V.
10,597,181US$196.8m-10.4%44.18%
8.26%
RA Capital Management, L.P.
8,845,000US$164.3m9.69%2.24%
6.52%
Viking Global Investors LP
6,978,534US$129.6m-13%0.42%
4.03%
Deerfield Management Company, L.P. Series C
4,314,340US$80.1m378%1.73%
3.79%
The Morningside Group Limited
4,060,923US$75.4m0%4.01%
3.74%
Jennison Associates LLC
3,998,541US$74.3m292%0.04%
3.04%
Cormorant Asset Management, LP
3,250,000US$60.4m31.6%4.06%
2.88%
Capital Research and Management Company
3,078,611US$57.2m0%no data
2.68%
Medicxi Ventures (UK) LLP
2,869,565US$53.3m0%12.11%
2.27%
Woodline Partners LP
2,430,782US$45.1m109%0.32%
2.16%
Wellington Management Group LLP
2,315,123US$43.0m2,410%0.01%
1.96%
Artal Group S.A.
2,095,638US$38.9m128%1.19%
1.74%
AllianceBernstein L.P.
1,858,065US$34.5m0%0.01%
1.63%
Polar Capital Holdings Plc
1,750,000US$32.5m16.3%0.12%
1.62%
Janus Henderson Group plc
1,736,777US$32.3m12.7%0.01%
1.08%
Pictet Asset Management Limited
1,157,452US$21.5m13.8%0.02%
0.98%
Adage Capital Management, L.P.
1,050,000US$19.5m-23.9%0.04%
0.91%
Citadel Advisors LLC
975,831US$18.1m86.8%0.02%
0.84%
TimesSquare Capital Management, LLC
895,574US$16.6m251%0.23%
0.76%
Michael Davidson
818,563US$15.2m0%no data
0.72%
Decheng Capital LLC
770,000US$14.3m30.5%3.83%
0.72%
Rock Springs Capital Management LP
767,522US$14.3m117%0.57%
0.63%
Medical Strategy GmbH, Asset Management Arm
671,177US$12.5m0%0.78%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 21:57
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Judah FrommerCredit Suisse
Debjit ChattopadhyayGuggenheim Securities, LLC
Antonio ArceH.C. Wainwright & Co.